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SUMMARY
Intestinal parasites are an important cause of morbidity and mortality. Immunocompromised individuals may develop more severe 
forms of these infections. Taking into account the immunity impairment in patients suffering from chronic renal failure (CRF), we 
will determine the prevalence and associated symptoms of intestinal parasites in these patients. Controls without CRF were used 
for comparison. Stool samples were collected and processed for microscopic identification of parasites using the Formalin-ether 
concentration method. For Cryptosporidium diagnosis, the ELISA technique was used. One hundred and ten fecal samples from 
hemodialysis patients were analyzed, as well as 86 from a community group used as control group. A result of 51.6% of intestinal 
parasites was observed in hemodialysis patients and 61.6% in the control group. Cryptosporidium and Blastocystis were the most 
common infections in patients with CRF (26.4% and 24.5%, respectively). Blastocystis was the most common infection in the control 
group (41.9%), however no individual was found positive for Cryptosporidium. Among the CRF patients, 73.6% were symptomatic, 
54.3% of these tested positive for at least one parasite, in contrast to 44.8% in asymptomatic patients (p = 0.38). The most common 
symptoms in this group were flatulence (36.4%), asthenia (30.0%) and weight loss (30.0%). In the control group, 91.9% were 
symptomatic, 60.8% of these tested positive for at least one parasite, in contrast to 71.4% in asymptomatic patients (p = 0.703). 
A significant difference between the two groups was observed with regard to symptoms, with bloating, postprandial fullness, and 
abdominal pain being more frequent in the control group than in the hemodialysis group (all p < 0.05). Comparing symptomatic 
with asymptomatic, there was no association in either group between symptoms or the prevalence of parasitic infection, nor with the 
type of parasite or with multiple parasitic infections. Patients with chronic renal failure are frequent targets for renal transplantation, 
which as well as the inherent immunological impairment of the disease itself, results in immunosuppression by medication. For this 
reason, carriers of intestinal parasites with pathogenic potential can develop serious clinical complications influencing the success of 
transplantation. This fact, coupled with the high prevalence of intestinal parasites and the dissociation between symptoms and infection 
in CRF patients, suggests that the stool test should be incorporated in routine propedeutics. Furthermore, preventive measures for the 
acquisition of parasites through the fecal-oral contamination route should be introduced.
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INTRODUCTION
Intestinal parasitosis constitutes a major public health problem, 
especially in developing countries, where inadequate sanitary conditions 
and lack of information result in the contamination of food and water 
sources, with a consequent perpetuation of parasite cycles. However, 
even in countries where adequate sanitation conditions and education 
predominate, some of these parasites play an important role in triggering 
diseases in specific groups such as immunocompromised individuals and 
young children10. Within the immunocompromised group are patients 
suffering from terminal chronic renal disease, which once established 
causes progressive and irreversible loss of kidney function leading to 
the need for renal replacement therapy16,22. Patients with chronic renal 
failure (CRF) undergoing hemodialysis are individuals whose immune 
system is significantly compromised. Among the changes related to 
immunodepression detected in these patients, we can cite the presence 
of uremic toxins which mainly impair the granulocytic but also the 
lymphocytic function3,4,9,14,21,23; malnutrition, present in a large number 
of patients35; vitamin deficiencies, resulting either from inadequate 
intake, or from losses during dialysis procedures9,14,23; blood exposure 
to artificial membranes with the inflammatory activation and release 
of cytokines, causing the activation of monocytes and the complement 
cascade that lead to a change in the immune response against infectious 
agents28, changes in the coagulation cascade; frequent and repeated 
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episodes of per-dialysis hypotension, with the activation of leukocytes, 
lymphocytes, and nitric oxide; platelet dysfunction and anemia causing 
specific immunological changes5,11,12,31; breaking of the cutaneous 
immune barrier and that of the mucosal surfaces, mainly due to functional 
changes in the surface of immunoglobulins, neutrophils, platelets, and 
the coagulation cascade9,14,17,30.
Due to a condition of such severe immunity impairment, studies have 
shown that patients suffering from chronic renal failure demonstrate an 
increased susceptibility to infections in general, but mainly to bacterial 
infections in the respiratory, digestive and urinary systems and in the 
skin. Such infections are responsible for somewhere between 14-40% 
of the deaths of these patients13,18,30.
Intestinal parasitosis, especially that caused by Cryptosporidium 
spp and Blastocystis hominis, has also been reported as a clinically 
important infection not only in immunocompromised patients but also 
in hemodialysis and renal transplant patients, with the prevalence data 
in these groups ranging from 15-25% and 20-35% respectively2,8,24,31,34. 
Such infections can cause uremic symptoms in patients to be aggravated, 
which as well as compromising their quality of life play an important role 
in the progress of those patients who will undergo kidney transplants.
Gastrointestinal symptoms are very common in patients with CRF 
on dialysis, especially hyporexia, diarrhea (chronic or acute), nausea, 
vomiting, and abdominal pain16,22. In most cases, chronic uremia may 
explain the occurrence of these symptoms. Chronic uremia however, may 
be an indication of other diseases such as intestinal parasitosis which 
exhibits similar symptoms, and the two conditions may therefore overlap. 
The investigation of parasitic infections in these patients, followed by any 
necessary treatment if tested positive, can therefore play an important 
role in the process of restoring the patients’ quality of life.
The present study determines the prevalence and symptoms 
associated with enteroparasitosis in CRF patients of the Dialysis Center 
of the Hospital Nossa Senhora das Graças, in Sete Lagoas, Minas 
Gerais, Brazil.
MATERIAL AND METHODS
This was a cross-sectional study, in which all hemodialysis patients 
were included who signed the consent form and completed the clinical 
standardized questionnaire containing data regarding the symptoms 
classically associated with intestinal parasitosis. The individuals in this 
group belong predominantly to low income households and are cared for 
by the public health system of Brazil (the Unified Health System - Ministry 
of Health). Three stool samples of each participant were collected on 
alternate days and stored in buffered formalin 10%. The fecal material 
was concentrated for microscopic identification of parasites using the 
Formalin-ether concentration method36. The morphological identification 
of Entamoeba histolytica was carried out in the laboratory of amoebiasis 
at the Federal University of Minas Gerais, which is considered a leading 
institution in the morphological and molecular diagnosis of this parasite. 
For diagnosing Cryptosporidium, the ELISA technique was used to identify 
coproantigens (Cryptosporidium II Test, Wampole®).
For comparison, fecal samples were collected from adults over 18 
years of age who did not suffer from any kidney problems, all from 
the Santa Maria community in Belo Horizonte which is comprised 
predominantly of low income families. Written consent was obtained 
from all study participants. These samples were processed in a similar 
way to those of hemodialysis patients. The same standardized clinical 
questionnaire was also applied.
This study was approved by the Ethical Review Committee of 
the Municipality Health Service of Belo Horizonte protocol number 
027/2007.
Data were presented as mean ± standard deviation or median 
with the interquartile range or as percentages and proportions. For the 
categorical variables, the chi-square or Fisher exact test was used and the 
t-Student or U-Mann-Whitney test was used for the continuous variables 
as appropriate. Differences with a p lower than 0.05 were considered 
statistically significant.
RESULTS
Feces were collected from a total of 110 dialysis patients with a 
mean age of 52.8 ± 14.8 years, 50.9% of them male. Twenty-eight 
patients (25.5%) were elderly patients aged 65 or older. Out of the 
110 samples, 57 (51.8%) tested positive for intestinal parasites, among 
them: Cryptosporidium, 29 (26.4%); Blastocystis hominis, 27 (24.5%); 
Endolimax nana, 22 (20.0%); Entamoeba coli, 7 (6.4%); E. histolytica/E. 
dispar, 4 (3.6%); Giardia lamblia, 1 (0.9%); Strongyloides stercoralis, 1 
(0.9%) (Table 1). Polyparasitism was present in 38.6% of dialysis patients.
Among the dialysis patients, 81 (73.6%) were symptomatic, 54.3% 
tested positive for some parasite in the stool test in contrast to 44.8% 
of asymptomatic individuals (OR = 1.464 - CI = 0.624 to 3.433 and p 
= 0.38). The most frequent symptoms among them were: flatulence, 
40 (36.4%); adynamia, 33 (30.0%); weight loss, 33 (30.0%); bloating, 
29 (26.4%); increased abdomen, 25 (22.7%); nausea or vomiting, 23 
(20.9%); postprandial fullness, 21 (19.1%); abdominal pain, 19 (17.3%); 
diarrhea, 12 (10.9%) (Table 3).
In the control group, 86 stool samples were collected from healthy 
adult individuals without kidney disease, who had a mean age of 41.5 
Table 1






N % N %
Cryptosporidium* 29 26.4 0 0.0 < 0.0001
Blastocystis hominis* 27 24.5 36 41.9 0.010
Endolimax nana 22 20.0 17 19.8 0.968
Entamoeba coli* 7 6.4 15 17.4 0.015
E. histolytica/E. dispar 4 3.6 4 4.7 0.732
Strongyloides stercoralis 1 0.9 0 0.0 1.000
Giardia lamblia 1 0.9 2 2.3 0.583*
*(p < 0.05)
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± 14.4 years, 57 (66.3%) of them male. Eight individuals (9.3%) 
were elderly patients aged 65 or older. Fifty-three samples (61.6%) 
were positive for intestinal parasites, with the following prevalence: 
Blastocystis hominis, 36 (41.9%); Endolimax nana, 17 (19.8%); 
Entamoeba coli, 15 (17.4%); E. histolytica/dispar, 4 (4.7%); Giardia 
lamblia, 2 (2.3%) (Table 1). Polyparasitism was present in 32.1% of 
control patients.
Among the control patients, 79 (91.9%) were symptomatic, 60.8% 
of whom tested positive for some parasite in the stool test, in contrast to 
71.4% of asymptomatic individuals (OR = 0.6 - CI = 0.11 - 3.39 and p 
= 0.703). The most frequent symptoms in this group were: postprandial 
fullness, 47 (54.7%); flatulence, 46 (53.5%); and abdominal pain, 36 
(41.9%) (Table 2).
When comparing the prevalence of parasites in both groups (Table 1), 
we found that Cryptosporidium was present only in the group of dialysis 
patients (p < 0.0001), and that the Blastocystis hominis and Entamoeba 
coli were significantly more prevalent in the control group (p < 0.05).
As for reported symptoms (Table 2), there was a significant difference 
between the two groups: flatulence, postprandial fullness and abdominal 
pain were more prevalent in the control group than in hemodialysis 
patients (all p < 0.05), but bloating showed up only in dialysis patients 
(p < 0.05).
However, when comparing the symptomatic and asymptomatic 
patients, no significant differences were detected in the prevalence of 
various parasites in both groups under study (Table 3).
When the symptoms in each group and the association with symptoms 
of infection by each parasite were assessed separately, no association was 
found. There was also no association with symptoms of polyparasitism. 
There was also no difference between hemodialysis patients and the 
control group regarding the ratio of patients with polyparasitism (38.6 
X 32.1 - p = 0.475).
There were significant differences between the two groups with 
regard to age (52.8 ± 14.8 years – dialysis patients X 41.5 ± 14.4 
years – control group – p < 0.0001), in the sex ratio (male - 50.9% in 
dialysis patients X 66.3% in the control group - p = 0.031), and in the 
ratio of elderly people (25.5% in dialysis patients X 9.3% in the control 
group). However, there was no correlation among age and sex with 
either symptoms, general and specific, or with infection, overall or by 
specific parasites.
Analyzing diabetic patients (data available only for hemodialysis 
group), of which 27 (24.5%) were diabetic patients, and 83 (75.5%) 
nondiabetic, we found no difference in the prevalence of intestinal 
parasitosis (37.0% for diabetic patients versus 56.6% in nondiabetic 
patients – p = 0.120), nor in the symptoms between the diabetic and those 
without diabetes (77.8% X 72.3% - p = 0.626), including each specific 
parasitosis or symptom.
Among the hemodialysis patients, 51% were suitable for renal 
transplantation, and 47.3% of them tested positive for some parasite 
Table 2






N % N %
Flatulence* 40 36.4 46 53.5 0.008
Adynamia 33 30.0 34 39.5 0.163
Weight loss 33 30.0 18 22.0 0.212
Bloating* 29 26.4 0 0 < 0.0001
Increased abdomen 25 22.7 27 31.8 0.157
Nausea or vomiting 23 20.9 13 15.1 0.299
Postprandial fullness* 21 19.1 47 54.7 < 0.0001
Abdominal pain* 19 17.3 36 41.9 < 0.0001
Diarrhea 12 10.9 17 19.8 0.050
*(p < 0.05)
Table 3
Relationship between parasite prevalence and symptoms in hemodialysis patients and in control group
Parasites





N % N % N % N %
Cryptosporidium 23 28.4 6 20.7 0.419 - - - - -
Blastocystis hominis 20 24.7 7 24.1 0.953 32 40.5 4 57.1 0.446
Endolimax nana 14 17.3 8 27.6 0.234 17 21.5 0 0.0 0.336
Entamoeba coli 5 6.2 2 6.9 1.000 13 16.5 2 28.6 0.600
E. histolytica/E.dispar 3 3.7 1 3.4 1.000 2 2.5 2 28.6 0.072
Strongyloides stercoralis 1 1.2 0 0.0 1.000 1 1.2 0 0.0 1.000
Giardia lamblia 1 1.2 0 0.0 1.000 2 2.5 0 0.0 1.000
Trichuris trichiura - - 1 0.8 1.000 1 0.9 0 0.0 1.000
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in the stool test. The two most frequent parasites were B. hominis, 14 
(27.5%) and Cryptosporidium, 11 (21.6%).
DISCUSSION
Studies determining the prevalence of enteroparasitosis in CRF 
patients on dialysis are scarce and have shown high infection rates, 
mainly by protozoa2,8,24,31,34. The impact of this parasitosis on the health 
of immunocompetent individuals is already known, and there may be 
impairment of the nutritional and immune condition culminating in an 
increased risk of bacterial, viral, and fungal co-infections35. Lower socio-
economic groups are associated with poor sanitation, inadequate hygiene 
habits, consumption of untreated water and malnutrition, leading to the 
onset of enteroparasitosis.
In the present study there was a high prevalence of parasitosis in 
both healthy subjects and hemodialysis patients (51.3% and 61.6% 
respectively), however there was no significant difference among them. 
Although both groups belong to a low income population, they live in 
communities with sewage systems and clean water, and lower prevalence 
rates would therefore be expected. It is possible that these groups have 
other sources of contamination and perpetuation of parasite cycles, 
which may include sources of contaminated food, poor information and 
a behavior pattern that favors contamination by enteroparasites.
Studies determining the prevalence of enteroparasites in chronic renal 
failure patients have shown rates ranging from 11% to 34%2,8,34. A study 
comparing 86 patients on hemodialysis and 146 healthy individuals found 
significant differences in the prevalence of enteroparasites between both 
groups (45.1% X 26.7% - p = 0.0318), and a greater ratio of polyparasitism 
in patients on dialysis (9.2% vs. 0.9% - p = 0.0019)19. In the present study, 
the high ratios of polyparasitism did not differ in these two groups (38.6 X 
32.1 - p = 0.475). Regional variations and socioeconomic characteristics 
between the two studies could explain such differences. In the present 
study, controls with similar socioeconomic characteristics to those of 
dialysis patients were included, such as individuals with a low level of 
education, an average family income of US$400.00, living in a population 
density of around 18,000.00 inhab/km2 and with water provided by the 
same water and sewage treatment company.
Diabetes mellitus is now the second largest cause of chronic 
renal disease. It leads to the simultaneous impairment of other organs 
also affecting the immune system. In this study, Diabetes mellitus 
was present in 24.5% of the hemodialysis group, while no data was 
available for the control group. However, a few studies have assessed 
the prevalence of intestinal parasitosis in this group. SEYRAFIAN et 
al. (2006) found a significant difference between the groups (diabetic 
x nondiabetic patients) regarding the prevalence of Cryptosporidium 
(19.4% vs. 8.3%, respectively - p < 0.05), but not in the occurrence of 
associated symptoms32. NAZLIGUL et al. (2001) found a significantly 
lower prevalence in diabetic patients than in the control subject group 
(47 vs. 55%, p, 0.05)25. ABAZA et al. (1995) designed a study to find out 
the prevalence of different intestinal opportunistic parasites in different 
groups of immunocompromised hosts, including diabetic and renal 
failure patients, with an 8% and 28.8% prevalence of intestinal parasitosis 
respectively1. BAIOMY et al. (2010) found the prevalence of intestinal 
parasitosis in 6% of both diabetic and renal failure patients, which was 
less than for patients suffering from malignancy (18%)6.
We found no difference in the prevalence of any parasites among 
diabetic and nondiabetic patients, and a comparison of these two groups 
showed no association between Diabetes mellitus and the symptoms. 
However, there is a lack of studies that have adequately assessed the 
symptoms of intestinal parasitosis in this group of patients.
Although there was a significant difference among the mean age, the 
sex ratio, and the number of elderly subjects between the two groups in 
the study, these variables were not associated with either the symptoms 
or with the prevalence of parasites. It is known that hemodialysis patients 
constitute a group of patients who are increasingly older, because at present 
it is a chronic renal disease resulting mainly from diseases such as Diabetes 
mellitus and systemic hypertension, which will most often lead the patient 
to the final stage of renal disease in later life. With regard to sex, it is 
possible that there were a greater number of males within the community.
Considering the symptoms and their association with parasitism, there 
was no association relating them to the presence of any parasites even 
when comparing symptomatic and asymptomatic patients in both groups. 
The presence of chronic uremia may mask some symptoms associated 
with intestinal parasitosis since some of the most frequent symptoms 
in patients suffering from both conditions are nausea, vomiting, and 
abdominal pain. It is therefore possible to misdiagnose enteroparasitosis 
which will cause the physician to overlook these symptoms. It may 
therefore be the case that certain symptoms reported by patients on 
dialysis were underestimated.
Our results are corroborated by studies which have been done on the 
prevalence of intestinal parasitosis in hemodialysis patients, especially 
when assessing the presence of Cryptosporidium and Blastocystis in these 
populations2,8,24,31,34. Cryptosporidium, B. hominis and Endolimax nana 
were the most frequent parasites in the hemodialysis group. Except for 
Cryptosporidium which was not found in the control group, the other two 
protozoa were found to be significant, and B. hominis prevailed. Such 
a result reinforces the theory of immunodeficiency as a determinant for 
Cryptosporidium infections.
Opportunistic diseases are closely related to immunodeficiency 
conditions2. Cryptosporidium is responsible for ephemeral and 
asymptomatic infections in the most immunocompetent individuals. 
Symptomatic and long-lasting infections are frequent in 
immunocompromised subjects10,34.
Blastocystis was the most common infection in the control group, and 
the second most frequent in the hemodialysis group after Cryptosporidium. 
This protozoan is among one of the most common organisms to be 
detected in stool specimens, but there has been considerable controversy 
regarding whether they represent a commensal organism or a true 
pathogen. The mode of transmission is not fully understood; fecal-oral 
transmission has been postulated7. Some authors have suggested that 
contaminated water may also be a source of infection15,20. Blastocystis 
spp have also been found in animals including pigs, monkeys, rodents 
and poultry. There seems to be poor host specificity; transmission occurs 
from human to human and between humans and animals29.
The prevalence varies between countries and between 
communities26,27,33. In general, the estimated prevalence of Blastocystis 
is higher in developing countries than in developed ones (30 to 50 
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percent and 5 to 10 percent respectively). There are fewer studies in 
hemodialysis patients assessing the prevalence of this organism. KULIK 
et al.19, who studied 86 hemodialysis patients and 145 healthy controls, 
found a Blastocystis prevalence of 20.9% and zero respectively, the most 
prevalent protozoan being in the first group.
Hemodialysis patients may be admitted at any time for a renal 
transplant and consequently to medicamental immunosuppression. In 
this case, carriers of enteroparasites with pathogenic potential may 
undergo significant clinical complications influencing the success of 
a transplant2,8,24,34. Considering the above and the high prevalence of 
parasitic infections found in patients on hemodialysis, the stool test 
should be incorporated into the routine propedeutics of these patients, 
coupled with preventive measures for the acquisition of parasites through 
the fecal-oral contamination route.
RESUMO
Prevalência de parasitismo intestinal e sintomatologia associada 
em pacientes hemodialíticos
Doenças parasitárias infectam grande número de indivíduos 
em todo o mundo. Manifestações clínicas mais severas podem se 
apresentar em pacientes imunocomprometidos. Considerando o 
importante comprometimento imunológico observado em pacientes 
com insuficiência renal crônica (IRC), foi determinada a prevalência 
e sintomas associados a parasitoses intestinais nesses pacientes em 
comparação a controles saudáveis. Foram coletadas amostras fecais 
de cada participante e processadas para identificação microscópica dos 
parasitas pelo método de concentração por formol-éter. Foi utilizada a 
técnica de ELISA para identificar coproantígenos de Cryptosporidium. 
Foram analisadas 110 amostras fecais de pacientes em hemodiálise e 
86 de um grupo controle comunitário. Cryptosporidium e Blastocystis 
foram as infecções mais freqüentes nos pacientes em hemodiálise (26,4% 
e 24,5%, respectivamente). Blastocystis foi a infecção mais freqüente 
no grupo controle (41,9%), entretanto nenhum indivíduo positivo para 
Cryptosporidium foi identificado. Considerando os pacientes com IRC, 
73,6% eram sintomáticos, sendo 54,3% positivos para algum parasita, 
contra 44,8% nos assintomáticos (p = 0,38). Os sintomas mais frequentes 
neste grupo foram flatulência (36,4%), adinamia (30,0%) e perda de 
peso (30,0%). No grupo controle, 91,9% eram sintomáticos, sendo 
60,8% positivos para algum parasita, contra 71,4% nos assintomáticos 
(p = 0,703). Em relação aos sintomas, houve diferença significativa 
entre os dois grupos, sendo que flatulência, plenitude pós-prandial, 
e dor abdominal foram mais freqüentes no grupo controle que nos 
pacientes em hemodiálise (todos p < 0,05). Comparando-se sintomáticos 
com assintomáticos, não houve associação entre a sintomatologia e a 
prevalência de parasitose, nem com o tipo de parasita, e nem com o 
poliparasitismo, nos dois grupos. Considerando que pacientes com IRC 
são frequentes alvos de transplante renal, resultando em imunossupressão 
por medicamentos, que é somada à deficiência imunológica inerente à 
própria doença. Os portadores de parasitas intestinais com potencial 
patogênico podem desenvolver sérias complicações clínicas que 
influenciam o sucesso do transplante. Este fato, aliado a alta prevalência 
de parasitas intestinais e dissociação entre os sintomas e infecção nesses 
pacientes, sugerem a incorporação do exame de fezes na propedêutica de 
rotina dos mesmos, juntamente com medidas preventivas para a aquisição 
de parasitas com rota de contaminação fecal-oral.
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